As the medical director and director of new clinical protocols, I welcome the opportunity to review the MEDOSI offering. The question being evaluated is How does Medosi products stack up against other CBD products in the market and the viability of Medosi products from a clinical outcomes and efficacy standpoint. Perhaps the first comments should center on the understanding and Scope of the Problems facing today’s clinicians with managing chronic conditions and acute problems. I will include two independent white papers regarding the current understanding of the Endocannabinoid system (ES) and the benefits of Hemp-Derived Phyto cannabinoids full spectrum CBD. I will then make observations regarding the MEDOSI platform.
Firstly, all clinicians are quite familiar with the burden of managing chronic disease conditions such as CHF, diabetes, osteoarthritis, dementia, allergies, endocrine disorders, liver and kidney disease, etc. The medical system has made tremendous advancements in developing treatment algorithms to help manage these conditions, as well as supportive platforms like improved monitoring systems, telemedicine, and patient education. Never before has there been such a need for a trusted clinician to patient bond to provide reliable and consistent access to the system. The alarming statistics on the rise of dementia and mental health issues in our aging population are staggering. Unfortunately, the best protocols and pharmaceuticals can only help patients to a certain level as more and more are realizing there are imperfect treatment options. A well-informed population is seeking innovative new technologies both as a treatment strategy, but also a preventative intervention.
Also, the medical community is challenged with the barrage of new mysterious syndromes rarely ever encountered 20-30 years ago. This includes syndrome diagnosis’ such as fibromyalgia, chronic fatigue syndrome, PANDAS, POTS, autoimmune conditions, elusive gastrointestinal syndromes. One consensus is that our immune systems and detoxification systems can no longer keep up with unprecedented accumulation of environmental chemicals in our air, food, and water. A food supply that is depleted of vital minerals and co-factors also contributes.
The changing paradigm is that progressive clinicians will need to take on a more holistic functional medicine philosophy that would also address COMMON DENOMINATORS that simultaneously should be addressed such as nutritional imbalances, impaired detoxification, leaky gut syndrome, food allergies, mold burden, stealth infection burden, systemic inflammation, neuroinflammation, EMF exposure, etc.
The CBD benefits on all of these physiologic systems is well documented.
Unfortunately,most of the data and studies were not taught or acknowledged in medicaleducation of clinicians until the most recent decade. This places a significant challenge forclinicians to review this vast body of work and effectively communicateadvantages and disadvantages of CBD products for various conditions. On top of the burden of managing a busypractice, it could be quite overwhelming to sort through the mountain ofinformation now available on line and journals, etc. This is now a consumer driven market, andpatients are expecting their trusted health advocate to stay abreast of all newtreatment innovations. So, it would seem prudent for a clinician or health careorganization to partner with a company such as MEDOSI that has a clinicianeducation platform that is developed by thought leaders in the CBDindustry. I will now comment on myobservations of the MEDOSI platform. Asa thirty year veteran in the family practice primary care setting, I have seenmany companies that at first glance may re reputable, but then fall far short of delivery. Also, as a member of A4M, International College of Integrative Medicine, the training from Trinity Schoolof Natural Health, and the training of the Functional Medicine University as aCertified Health Coach, I have been fortunate to be exposed to a lot of the research on the EC system and the benefits of CBD utilization.
One attractive feature that would be appreciated by clinicians is how MEDOSI is dedicated to educating health and wellness on the benefits and safe use of CBD products. It is more reassuring to a professional practice to partner with a company with this philosophy, instead of trying to saturate all retail settings. I appreciate how they emphasize that the relationship with a clinician is a partnership, and that MEDOSI is there to help navigate the regulatory landscape. Since the market regulations are always changing, it is helpful to have experienced pharmacists, physicians, product formulators, compliance officers, quality control officers, and legal experts who have years of experience in their respective fields. There is a comfort that the TEAM PROFILE section of the introduction brochure provides extensive details of the resume of each individual. I was particularly impressed with the VIMEO production that was very professionally produced. I like the fact that it was concise, accurate, and only around 20 plus minutes----the average attention span for a busy clinician! I found it highly convincing that this would be an ideal well- rounded team to collaborate with.
The introduction brochure does an excellent job of positioning MEDOSI as a Single Source Solution for health and wellness professionals. Reassuring comments about product quality emphasizes all natural, organically grown, and non-GMO sourced hemp. The USA production facility is federally registered and ISO, CGMP certified. Third party testing is done for metals, lead, and pesticides. Pricing is reported 50% less than leading competitors. There is training for the clinical staff, and there is a dedicated account executive and marketing team for each practice. A very impressive addition is a toll-free telephone and email support staff for patient questions. A Medical Advisor with deep cannabinoid knowledge is available. There is a 90-day money back guarantee, and clinicians can start with individual SKU’s or complete counter display. Therefore, a clinician should have very little concern about the barrier to entry or risk of committing to a new clinical initiative.
The educational handouts for waiting room are very professionally produced and clinically relevant. I am particularly impressed with the marketing piece that emphasizes the dosing regimen is definitely not a “one size fits all”. Most conferences I have attended with experts in the field of EC and CBD usage, all speakers emphasized this vital importance of educating the patient on this philosophy of finding the CBD Sweet Spot regarding dosage. It is an excellent idea to provide the featured MEDOSI Dosing Journal that facilitates a meaningful dialogue with the clinician and patient for optimal outcomes.
Again, I think all progressive and curious clinicians are interested in learning more about this industry with a concise and bullet point information piece. I like the Market Insights comments regarding the 2020 market to reach 4.7 billion and expected to increase 14% by 2025. I found it interesting that Edibles are the most popular way to consume, with an 88% growth projection using the gummies. The Consumer Insights section shows some very interesting statistics that I think all clinicians would find surprising and quite useful to developing better insight in to this market. 56% of US adults do not understand the difference between THC and CBD, and 59% are confused abut the effects or side effects of hemp-derived products. This underscores even more profoundly as to why patients really need their trusted health care advocate to be well informed and offer a respected, pure product offering.
I am very impressed with the MEDOSI Point-Of-Sale Display of products for waiting room display. I like the fact that there are not too many products, but also flexibility of gummies, tinctures, and topicals. This will definitely promote a lot of questions from clients to the providers and generate rapid sales once a client is educated and assured of safety, proven efficacy, and affordability.
I was somewhat blown away with the price points presented in the document titled “Leading Competitors Pricing Matrix Comparison”. Most clinicians have most likely have heard of most of these competitors such as: Amanda, Pure Kana, Nu Leaf, Green Roads, and Charlottes Web. In my mind, this is quite impressive that the price points are quite significantly lower, acknowledging that MEDOSI is also able to also offer such a ROBUST supportive clinical program with staff support, patient support, marketing support, clinician education support, etc.
For all of the observations noted above, I would have no hesitation of proudly presenting this relevant and profitable clinical revenue generating platform to all existing practices and new start-ups. I am familiar with the fact that the ALL CARE/PHYSICIANS CONCIERGE network is vast and well represented across the USA. Also of note is the positive feedback received from PCC reps who have provided MEDOSI products to some of their providers and office managers, and the feedback thus far has been positive with respect to mitigation of chronic and acute pain. This would be an ABSOLUTE great pairing with all of these clinical initiatives already in place. ACC had done an excellent job over the years of helping practices to establish themselves as a true “CENTER OF EXCELLENCE” in their geographic area. This would be another excellent addition of a platform than continues to promote the philosophy of the profound THERAPEUTIC SYNERGISTIC ADVANTAGE when combining a holistic blend of platforms for any condition. Another reason as to why this would be an ideal collaboration?? The ACC model of offering practices unique financing options that can BUNDLE many initiatives in an “easy to swallow” start-up expense for medical and wellness practices could integrate a MEDOSI initiative quite efficiently.